Rocket Pharmaceuticals Valuation Multiples

Rocket Pharmaceuticals Overview

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Founded

1999

HQ

Employees

299

Website

rocketpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5M

EBITDA: ($176M)

EV

$263M

Valuation Multiples

Multiples.vc

Start free trial

Rocket Pharmaceuticals Financials

Rocket Pharmaceuticals reported last 12-month revenue of $5M and negative EBITDA of ($176M).

In the same LTM period, Rocket Pharmaceuticals generated $5M in gross profit, ($176M) in EBITDA losses, and had net loss of ($202M).

Rocket Pharmaceuticals P&L

In the most recent fiscal year, Rocket Pharmaceuticals reported revenue of — and EBITDA of ($210M).

Rocket Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Rocket Pharmaceuticals Stock Performance

Rocket Pharmaceuticals has current market cap of $427M, and enterprise value of $263M.

Rocket Pharmaceuticals' stock price is $3.91.

Rocket Pharmaceuticals Valuation Multiples

Rocket Pharmaceuticals trades at 48.9x EV/Revenue multiple, and (1.5x) EV/EBITDA.

Rocket Pharmaceuticals Financial Valuation Multiples

As of April 18, 2026, Rocket Pharmaceuticals has market cap of $427M and EV of $263M.

Equity research analysts estimate Rocket Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Rocket Pharmaceuticals has a P/E ratio of (2.1x).

Rocket Pharmaceuticals Margins & Growth Rates

Rocket Pharmaceuticals' revenue in the last 12 month grew by 240%.

Rocket Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.

Rocket Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Rocket Pharmaceuticals M&A Activity

Rocket Pharmaceuticals acquired XXX companies to date.

Last acquisition by Rocket Pharmaceuticals was on XXXXXXXX, XXXXX. Rocket Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Rocket Pharmaceuticals Investment Activity

Rocket Pharmaceuticals invested in XXX companies to date.

Rocket Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Rocket Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).